(c) 2024 PillSync.com

21 Desogestrel 0.15 MG Ethinyl Estradiol 0.03 MG Oral Tablet 7 Inert Ingredients 1 MG Oral Tablet Pack Isibloom 28 Day

INDICATIONS AND USAGE Isibloom (desogestrel and ethinyl estradiol tablets) are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant System depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates. In a clinical trial with desogestrel and ethinyl estradiol tablets, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported. This represents an overall user-efficacy (typical user-efficacy) pregnancy rate of 1.12 per 100 women-years. This rate includes patients who did not take the drug correctly. TABLE 1: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND THE FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR. UNITED STATES. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year a Method (1) Typical Use b (2) Perfect Use c (3) (4) Chance f 85 85 Spermicides g 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-Thermal h 2 Post-Ovulation 1 Withdrawal 19 4 Cap i Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm i 20 6 56 Condom j Female (Reality ® ) 21 5 56 Male 14 3 61 Pill 5 71 Progestin Only 0.5 Combined 0.1 IUD Progesterone T 2 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera 0.3 0.3 70 Norplant ® and Norplant-2 ® 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. d Lactation Amenorrhea Method: LAM is a highly effective, temporary method of contraception. e Source: Trussel J. Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowel D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York, NY; Irvington Publishers, 1998. a Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. b Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. c Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. d The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The FDA has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 4 yellow pills). e However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency of duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. f The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. g Foams, creams, gels, vaginal suppositories, and vaginal film. h Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. i With spermicidal cream or jelly. j Without spermicides. Desogestrel and ethinyl estradiol tablets have not been studied for and are not indicated for use in emergency contraception.

xiromed, llc.


4 years ago ROUND ORANGE SZ D2 21 Desogestrel 0.15 MG  Ethinyl Estradiol 0.03 MG Oral Tablet  7 Inert Ingredients 1 MG Oral Tablet  Pack Isibloom 28 Day

ROUND ORANGE SZ D2

4 years ago ROUND ORANGE SZ D2 21 Desogestrel 0.15 MG  Ethinyl Estradiol 0.03 MG Oral Tablet  7 Inert Ingredients 1 MG Oral Tablet  Pack Isibloom 28 Day

SZ D2 ROUND ORANGE

HOW SUPPLIED Isibloom (

DESOGESTREL AND ETHINYL ESTRADIOL tablets USP), 0.15 mg/0.03 mg are available as follows: Each blister card contains 21 active tablets and 7 inactive tablets. The 21 active tablets are round, orange, film-coated, debossed with SZ on one side and D2 on the other side. The 7 inert tablets are round, green, film-coated, debossed with SZ on one side and J1 on the other. NDC 70700-113-85, Carton containing 3 blister cards STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].


More pills like ROUND SZ D2












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site